Oculis Holding AG (OCS) stock price, financials & research

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

27/100

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

14

Overpriced

Momentum

19

Strong Down

Sentiment

63

Bullish

Risk resilience

37

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Oculis Holding AG is a biopharmaceutical company in the clinical development stage, specializing in the creation of innovative eye drop medications for various ocular conditions, addressing both the anterior and posterior segments of the eye. A key asset in its therapeutic portfolio is OCS-01, a topical formulation of dexamethasone, currently progressing through Phase 3 clinical trials for the management of diabetic macular edema. Additionally, OCS-02, a topically administered biological candidate, is engaged in Phase 2b clinical studies to treat keratoconjunctivitis sicca, commonly known as dry eye disease. The company is also advancing OCS-05, an innovative neuroprotective agent, which targets acute optic neuritis and an array of other neuro-ophthalmic disorders, including glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. This enterprise maintains its headquarters in Zug, Switzerland.

Industry: Biotechnology
Sector: Healthcare
Headquarters: CH
CEO: Riad Sherif
Listed since: May 18, 2021
Employees: 60

Market position

Day range

Current $13.085

$13.00$13.22

52-week range

Current $13.085

$10.52$34.475

Open: $13.17
Previous close: $13.14
Volume: 76.45K; 0.13× average
Average volume: 591.55K; Average daily volume
Market cap: 748.06M USD
Beta: 0.23; Market reference 1
50-day average: $12.3556; +5.90% above average
200-day average: $21.3842; -38.81% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value: 750.2M CHF
EV / EBITDA: -8.03×
Earnings yield: -11.40%
Free cash flow yield: -7.54%

Profitability & efficiency

Return on equity: -48.15%
Return on assets: -40.01%
Return on invested capital: -39.58%

Financial health

Current ratio: 5.96×
Altman Z-score: 9.18
Piotroski F-score: 4 of 9

Financial statements

Income trends

Operating income

−79.15M CHF-8.12%

Net income

−94.51M CHF-10.18%

Metric (CHF)	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	—	686K CHF	—	—	—
Cost of goods sold	—	52.08M CHF	—	—	—
Gross profit	—	−51.4M CHF	—	—	—
Research and development	54.52M CHF	52.08M CHF	29.25M CHF	22.22M CHF	9.57M CHF
Selling, general, and administrative	24.63M CHF	21.81M CHF	14.72M CHF	6.74M CHF	4.1M CHF
Operating expenses	79.15M CHF	21.81M CHF	80.71M CHF	32.38M CHF	13.23M CHF
Interest income	1.69M CHF	2.17M CHF	1.59M CHF	126K CHF	21K CHF
Interest expense	795.55K CHF	639K CHF	1.46M CHF	6.44M CHF	5.12M CHF
Depreciation and amortization	521.45K CHF	406K CHF	287K CHF	299K CHF	235K CHF
Operating income	−79.15M CHF	−73.2M CHF	−80.71M CHF	−32.38M CHF	−13.23M CHF
Net income	−94.51M CHF	−85.78M CHF	−88.8M CHF	−38.7M CHF	−18.55M CHF

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate: 27%; 3 beats, 8 misses, 0 met estimates
Average EPS surprise: -10.13%; 11 comparable reports
Latest EPS result: -0.2; Estimate -0.48 · Beat by 58.33%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$39.40

201.11% upside

Past 12 months12-month forecastHigh $50.00Average $39.40Low $26.00

Rating distribution

9 ratings

Strong buy00%

Buy9100%

Hold00%

Sell00%

Strong sell00%

Recent analyst actions

9 institutions

GuggenheimmaintainBuyJun 1, 2026

OCS news

globenewswire.comAug 24, 2026

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announces that the…

Read source

globenewswire.comAug 14, 2026

Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

ZUG, Switzerland, Aug. 14, 2026 (GLOBE NEWSWIRE) -- The attached notifications relate to the vesting and settlement of RSUs previously granted to directors of the Company.

Read source

zacks.comAug 14, 2026

Does Oculis Holding AG (OCS) Have the Potential to Rally 187.83% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 187.8% in Oculis Holding AG (OCS). While the effectiveness of this highly sought-after metric is questionable, the positive trend…

Read source

globenewswire.comAug 10, 2026

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis' Position as an Emerging Leading Neuro-Ophthalmology Company

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address…

Read source

zacks.comAug 6, 2026

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) came out with a quarterly loss of $0.2 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.59 per share a year ago.

Read source

globenewswire.comAug 6, 2026

Oculis Reports Q2 2026 Financial Results and Provides Company Update

ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs…

Read source